Movement Alert｜WuXi Biologics Rises 3.24% in Regular Trading, Star Fund Manager Zhao Feng Adds Stock as New Top-10 Holding

Market Focus07-20 09:56

On July 20, WuXi Biologics rose 3.24% in regular trading, trading at 38.66 HKD/share, with turnover of approximately 202 million HKD.

On the news front, Ruiyuan Fund's prominent fund manager Zhao Feng disclosed in the Q2 report of his Ruiyuan Balanced Value Three-Year Holding Fund that WuXi Biologics has newly entered the fund's top-10 holdings, with a position weight of approximately 4.34%. This marks Zhao's return to the stock after a one-year absence, sending a strong institutional confidence signal to the market.

The broader Life Sciences Tools and Services sector rallied in tandem, with Joinn Laboratories up 7.24%, Pharmaron up 5.69%, WuXi XDC up 4.13%, Insilico Medicine up 4.12%, and WuXi AppTec up 2.48%. The stock had previously dropped 5.95% on July 17 amid sector-wide weakness, and the combination of the star fund manager's endorsement and sector recovery triggered a technical rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128018085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 09:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128018085","market":"us","top_or_hot":-1,"title":"Movement Alert｜WuXi Biologics Rises 3.24% in Regular Trading, Star Fund Manager Zhao Feng Adds Stock as New Top-10 Holding","media":"Market Focus","content":"<p><p>On July 20, WuXi Biologics rose 3.24% in regular trading, trading at 38.66 HKD/share, with turnover of approximately 202 million HKD.</p><p>On the news front, Ruiyuan Fund's prominent fund manager Zhao Feng disclosed in the Q2 report of his Ruiyuan Balanced Value Three-Year Holding Fund that WuXi Biologics has newly entered the fund's top-10 holdings, with a position weight of approximately 4.34%. This marks Zhao's return to the stock after a one-year absence, sending a strong institutional confidence signal to the market.</p><p>The broader Life Sciences Tools and Services sector rallied in tandem, with Joinn Laboratories up 7.24%, Pharmaron up 5.69%, WuXi XDC up 4.13%, Insilico Medicine up 4.12%, and WuXi AppTec up 2.48%. The stock had previously dropped 5.95% on July 17 amid sector-wide weakness, and the combination of the star fund manager's endorsement and sector recovery triggered a technical rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi Biologics Rises 3.24% in Regular Trading, Star Fund Manager Zhao Feng Adds Stock as New Top-10 Holding</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi Biologics Rises 3.24% in Regular Trading, Star Fund Manager Zhao Feng Adds Stock as New Top-10 Holding\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-20 09:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 20, WuXi Biologics rose 3.24% in regular trading, trading at 38.66 HKD/share, with turnover of approximately 202 million HKD.</p><p>On the news front, Ruiyuan Fund's prominent fund manager Zhao Feng disclosed in the Q2 report of his Ruiyuan Balanced Value Three-Year Holding Fund that WuXi Biologics has newly entered the fund's top-10 holdings, with a position weight of approximately 4.34%. This marks Zhao's return to the stock after a one-year absence, sending a strong institutional confidence signal to the market.</p><p>The broader Life Sciences Tools and Services sector rallied in tandem, with Joinn Laboratories up 7.24%, Pharmaron up 5.69%, WuXi XDC up 4.13%, Insilico Medicine up 4.12%, and WuXi AppTec up 2.48%. The stock had previously dropped 5.95% on July 17 amid sector-wide weakness, and the combination of the star fund manager's endorsement and sector recovery triggered a technical rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1128018085","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128018085","pubTimestamp":1784512595,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 20, WuXi Biologics rose 3.24% in regular trading, trading at 38.66 HKD/share, with turnover of approximately 202 million HKD.On the news front, Ruiyuan Fund's prominent fund manager Zhao Feng...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"动向提醒|药明生物常规交易上涨3.24%，明星基金经理赵峰新增股票为前10大重仓股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On July 20, WuXi Biologics rose 3.24% in regular trading, trading at 38.66 HKD/share, with turnover of approximately 202 million HKD.On the news front, Ruiyuan Fund's prominent fund manager Zhao Feng disclosed in the Q2 report of his Ruiyuan Balanced Value Three-Year Holding Fund that WuXi Biologics has newly entered the fund's top-10 holdings, with a position weight of approximately 4.34%. This marks Zhao's return to the stock after a one-year absence, sending a strong institutional confidence signal to the market.The broader Life Sciences Tools and Services sector rallied in tandem, with Joinn Laboratories up 7.24%, Pharmaron up 5.69%, WuXi XDC up 4.13%, Insilico Medicine up 4.12%, and WuXi AppTec up 2.48%. The stock had previously dropped 5.95% on July 17 amid sector-wide weakness, and the combination of the star fund manager's endorsement and sector recovery triggered a technical rebound.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128018085","isCrawlerRequest":true}